Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: We evaluated the efficacy and safety of daclatasvir (DCV) and asunaprevir (ASV) in patients with chronic hepatitis C virus (HCV) infection on hemodialysis. Methods: We performed a single-arm, multicenter prospective study. Twenty-one chronic hemodialysis patients with HCV infection were prospectively enrolled from February 2016 to April 2017. We evaluated the virological responses at weeks 4, 12, and 24 (end of treatment [EOT]) and the sustained virological response at 12 weeks after the EOT (SVR12). The tolerability and safety of the drugs were also assessed. Results: None of the 20 patients had the NS5A resistance-associated variant (NS5A RAV), and one patient was indeterminate for the NS5A RAV. Seventeen patients (80%) completed the 24 weeks of treatment with DCV and ASV. Four patients discontinued the study prior to week 12. In an intention-to-treat analysis, the SVR12 was 76.1%. In a per-protocol analysis, patients who completed DCV and ASV treatment achieved an SVR12 of 100%. DCV and ASV were well tolerated by the majority of patients. Three patients discontinued treatment due to adverse events (AEs) including dizziness, dyspnea, and neutropenia. The patient with indeterminate NS5A RAV showed viral breakthrough and discontinued treatment. Conclusions: DCV and ASV combination therapy in chronic hemodialysis patients with HCV infection achieved a high SVR12 rate with few AEs. To maximize the SVR12 rate, it is important to identify candidates by baseline RAV testing. Close monitoring of the safety and tolerability of DCV and ASV may be necessary in HCV-infected patients on hemodialysis. (ClinicalTrials.gov ID NCT02580474)
Abstract
Background/Aims: We evaluated the efficacy and safety of daclatasvir (DCV) and asunaprevir (ASV) in patients with chronic hepatitis C virus (HCV) infection on hemodialysis. Methods: We performed a single-arm, multicenter prospective study. Twenty-one chronic hemodialysis patients with HCV infection were prospectively enrolled from February 2016 to April 2017. We evaluated the virological responses at weeks 4, 12, and 24 (end of treatment [EOT]) and the sustained virological response at 12 weeks after the EOT (SVR12). The tolerability and safety of the drugs were also assessed. Results: None of the 20 patients had the NS5A resistance-associated variant (NS5A RAV), and one patient was indeterminate for the NS5A RAV. Seventeen patients (80%) completed the 24 weeks of treatment with DCV and ASV. Four patients discontinued the study prior to week 12. In an intention-to-treat analysis, the SVR12 was 76.1%. In a per-protocol analysis, patients who completed DCV and ASV treatment achieved an SVR12 of 100%. DCV and ASV were well tolerated by the majority of patients. Three patients discontinued treatment due to adverse events (AEs) including dizziness, dyspnea, and neutropenia. The patient with indeterminate NS5A RAV showed viral breakthrough and discontinued treatment. Conclusions: DCV and ASV combination therapy in chronic hemodialysis patients with HCV infection achieved a high SVR12 rate with few AEs. To maximize the SVR12 rate, it is important to identify candidates by baseline RAV testing. Close monitoring of the safety and tolerability of DCV and ASV may be necessary in HCV-infected patients on hemodialysis. (ClinicalTrials.gov ID NCT02580474)
참고문헌 (26)
- Westbrook RH, "Natural history of hepatitis C", J Hepatol, 61(1 Suppl), pp.S58~S68 (2014)
- Mohd Hanafiah K, "Global epidemiology of hepatitis C virus infection : new estimates of age-specific antibody to HCV seroprevalence", Hepatology, 57, pp.1333~1342 (2013)
- Johnson DW, "Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries : analysis of registry data", Nephrol Dial Transplant, 24, pp.1598~1603 (2009)
- 진동찬, "Current characteristics of dialysis therapy in Korea: 2015 registry data focusing on elderly patients", Kidney Research and Clinical Practice, 35(4), pp.204~211 (2016), 대한신장학회
- Jadoul M, "The changing epidemiology of hepatitis C virus(HCV)infection in haemodialysis : European multicentre study", Nephrol Dial Transplant, 19, pp.904~909 (2004)
- Pockros PJ, "Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease", Gastroenterology, 150, pp.1590~1598 (2016)
- Park H, "A metaanalytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection", J Viral Hepat, 22, pp.897~905 (2015)
- Lai TS, "Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease : REVEALHCV study", Hepatology, 66, pp.784~793 (2017)
- Fabrizi F, "The impact of hepatitis C virus infection on survival in dialysis patients : meta-analysis of observational studies", J Viral Hepat, 14, pp.697~703 (2007)
- Carvalho-Filho RJ, "Management of hepatitis C in patients with chronic kidney disease", World J Gastroenterol, 21, pp.408~422 (2015)
- Morales JM, "Kidney transplantation in the patient with hepatitis C virus infection", Contrib Nephrol, 176, pp.77~86 (2012)
- 조병욱, "Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study", Clinical and Molecular Hepatology, 23(1), pp.51~56 (2017), 대한간학회[DOI]
- Garimella T, "Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment", Antivir Ther, 20, pp.535~543 (2015)
- Eley T, "Asunaprevir : a review of preclinical and clinical pharmacokinetics and drug-drug interactions", Clin Pharmacokinet, 54, pp.1205~1222 (2015)
- AASLD, "Hepatitis C guidance: AASLDIDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus", Hepatology, 62, pp.932~954 (2015)
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines : management of hepatitis C", Clin Mol Hepatol, 22, pp.76~139 (2016)
- European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C 2016", J Hepatol, 66, pp.153~194 (2017)
- Ahn SB, "Efficacy and safety of pegylated interferon base treatment in patients with chronic hepatitis C on dialysis", Eur J Intern Med, 26, pp.292~296 (2015)
- Liu CH, "Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis : a randomized trial", Ann Intern Med, 159, pp.729~738 (2013)
- Kumada H, "Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon", ribavirin in Japanese hepatitis C virus patients, 2016, pp.31, 14~22
- McPhee F, "High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms", Adv Ther, 32, pp.637~649 (2015)
- Toyoda H, "Safety and efficacy of dual direct-acting antiviral therapy(daclatasvir and asunaprevir)for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis", J Gastroenterol, 51, pp.741~747 (2016)
- Suda G, "Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C", J Gastroenterol, 51, pp.733~740 (2016)
- Kwo P, "Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatmentexperienced patients with chronic hepatitis C infection", Gastroenterology, 152, pp.164~175 (2017)
- Roth D, "Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease(the C-SURFER study) : a combination phase 3 study", Lancet, 386, pp.1537~1545 (2015)
- Gane E, "Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment", N Engl J Med, 377, pp.1448~1455 (2017)